Coherus Oncology, Inc. (CHRS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 165.32M USD. 52-week range 0.9740 to 2.62 USD. Data as of 2026-10-09.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an ...